CEO-Controlled Entity Disposes of 8.5% of Liminatus Pharma Shares Without Consideration
LIMN sits 48% above its 52-week low of $0.095 on elevated volume (2.7× avg).
Summary
Valetudo Therapeutics, an entity controlled by CEO Chris Kim, disposed of 4.37 million shares of Liminatus Pharma, representing 8.5% of the company, to Ewon Comfortech Co., Ltd. The transfer involved no cash consideration, and Valetudo retains voting power.
Key Events · Ownership and Investor Activity · LIMN
-
Significant Share Disposition by CEO-Controlled Entity
Valetudo Therapeutics LLC, controlled by CEO Chris Kim, disposed of 4,373,603 shares of common stock, representing 8.5% of the company's market capitalization.
-
Transfer Without Cash Consideration
The shares were transferred to Ewon Comfortech Co., Ltd. without any payment of consideration, though Valetudo Therapeutics retains voting power over these shares.
-
Context of Recent Corporate Activity
This disposition occurred on June 24, 2026, the same day an S-1 registration for resale by Armistice Capital was filed, and amidst the company's recent acquisition of InnocsAI and ongoing financial and delisting challenges.
Analysis · LIMN · Life Sciences
Valetudo Therapeutics LLC, an entity controlled by CEO Chris Kim, transferred a substantial block of 4.37 million shares, representing 8.5% of the company's market capitalization, to Ewon Comfortech Co., Ltd. While the transaction involved no cash consideration and Valetudo retains voting power, this still marks a significant shift in direct ownership for a key insider. This disposition occurred on the same day an S-1 registration for resale by another investor was filed, and amidst the company's ongoing financial challenges, including a going concern warning, a recent Nasdaq delisting notice, and the completion of a major acquisition.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LIMN was trading at $0.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.10 to $10.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.